Over the past decade, high-dose chemotherapy followed by autologous bone marrow support (ABMS) has been employed with increasing frequency to treat patients with a variety of solid tumors. This paper explores the rationale and relevant clinical data for the use of this approach to treat patients with breast and ovarian cancer for the solid tumors of which ABMS is most commonly employed.